| |
Phenotype and functionality of the infusion products
|
Clinical outcome
|
|---|
|
Patient number
|
Infused cells
|
CD8+
|
CD45RO+
|
CCR7+
|
CD27+
|
Reactivitya
|
Total number of responding CD8+ T cells infused
|
Response
|
TTP
|
OS
|
|---|
| |
(x 1010)
|
(%)
|
(%)
|
(%)
|
(% of CD8)
|
(%)
|
(x 106)
|
(RECIST)
|
(mo)
|
(mo)
|
|---|
|
1
|
2.9
|
94
|
99.7
|
7.5
|
6.1
|
28.8
#
|
6460
|
CR
|
30+
|
30+
|
|
2
|
1.8
|
92
|
97.4
|
4.9
|
5.2
|
1.0#
|
175
|
PD
|
2
|
7
|
|
3
|
2.0
|
95
|
99.4
|
6.1
|
0.5
|
0.0#
|
7
|
SD
|
4
|
11.5
|
|
6
|
0.3
|
47
|
98.4
|
3.9
|
1.2
|
0.9*
|
41
|
PD
|
2
|
4.6
|
|
7
|
1.3
|
88
|
89
|
31.8
|
3.4
|
0.4#
|
44
|
SD
|
5
|
11
|
|
11
|
7.5
|
95
|
99
|
0.6
|
8.1
|
6.0*
|
4377
|
CR
|
10+
|
10+
|
- Table showing phenotypic and functional characteristics of the infusion products as well as clinical outcome for the 6 treated patients.
- aReactivity meaning tumor-specific CD8+ T cells in % of infused TILs. Reactivity was calculated by intracellular cytokine staining measuring the percentage of CD8+ T cells expressing TNF-α and IFN-γ after co-culture with *autologous tumor cell lines or #allogeneic melanoma cell lines. For patients tested against several allogeneic melanoma cell lines reactivity against the cell line that resulted in the highest reactivity has been shown (for further details please see Additional file 2). RECIST: Response Evaluation Criteria in Solid Tumors, TTP: time to progression, OS: overall survival, mo: months, CR: complete response, SD: stable disease, PD: progressive disease.
